Verrica Pharmaceuticals
VRCA
59 hedge funds and large institutions have $84.2M invested in Verrica Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 11 closing their positions.
483% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $227K
183% more capital invested
Capital invested by funds: $29.8M → $84.2M (+$54.4M)
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
18% more funds holding
Funds holding: 50 → 59 (+9)
0.46% more ownership
Funds ownership: 2.63% → 3.09% (+0.46%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$16M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.26M |
| 3 |
Morgan Stanley
New York
|
+$914K |
| 4 |
Jane Street
New York
|
+$698K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$575K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$5.81M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.43M |
| 3 |
Renaissance Technologies
New York
|
-$604K |
| 4 |
CI
Conning Inc
Hartford,
Connecticut
|
-$355K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$355K |
VRCA Hedge Fund Activity: Q1 2023 in Review
59 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2023, worth a combined $84.2M — up 183% from $29.8M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VRCA positions and 11 closed out — a net gain of 10 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $16M. The largest seller was BML Capital Management, cutting an estimated $5.81M.
- 59 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2023, up from 50 in Q4 2022.
- Funds reported $84.2M of Verrica Pharmaceuticals stock for Q1 2023, up 183% quarter-over-quarter.
- 21 funds opened new Verrica Pharmaceuticals positions in Q1 2023 and 11 closed out, a net change of +10 holders.
- The largest Verrica Pharmaceuticals buyer in Q1 2023 was Avoro Capital Advisors, an estimated $16M added.
- The largest Verrica Pharmaceuticals seller in Q1 2023 was BML Capital Management, an estimated $5.81M sold.
Based on aggregated 13F filings for Q1 2023.